These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 37874836)
1. Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2. Longsompurana P; Rungrotmongkol T; Plongthongkum N; Wangkanont K; Wolschann P; Poo-Arporn RP PLoS One; 2023; 18(10):e0293263. PubMed ID: 37874836 [TBL] [Abstract][Full Text] [Related]
2. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain. Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099 [TBL] [Abstract][Full Text] [Related]
3. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. Sun D; Sang Z; Kim YJ; Xiang Y; Cohen T; Belford AK; Huet A; Conway JF; Sun J; Taylor DJ; Schneidman-Duhovny D; Zhang C; Huang W; Shi Y Nat Commun; 2021 Aug; 12(1):4676. PubMed ID: 34344900 [TBL] [Abstract][Full Text] [Related]
4. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421 [TBL] [Abstract][Full Text] [Related]
6. Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD. Tragni V; Mercurio I; Paoletti DP; Onofrio A; Laera L; Cafferati Beltrame L; Sgobba MN; Guerra L; Volpicella M; De Grassi A; Elia G; Pierri CL J Med Virol; 2023 Jun; 95(6):e28875. PubMed ID: 37338047 [TBL] [Abstract][Full Text] [Related]
7. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. Wagner TR; Schnepf D; Beer J; Ruetalo N; Klingel K; Kaiser PD; Junker D; Sauter M; Traenkle B; Frecot DI; Becker M; Schneiderhan-Marra N; Ohnemus A; Schwemmle M; Schindler M; Rothbauer U EMBO Rep; 2022 Feb; 23(2):e53865. PubMed ID: 34927793 [TBL] [Abstract][Full Text] [Related]
8. Structural basis of nanobodies neutralizing SARS-CoV-2 variants. Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082 [TBL] [Abstract][Full Text] [Related]
9. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
10. NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. Wagner TR; Ostertag E; Kaiser PD; Gramlich M; Ruetalo N; Junker D; Haering J; Traenkle B; Becker M; Dulovic A; Schweizer H; Nueske S; Scholz A; Zeck A; Schenke-Layland K; Nelde A; Strengert M; Walz JS; Zocher G; Stehle T; Schindler M; Schneiderhan-Marra N; Rothbauer U EMBO Rep; 2021 May; 22(5):e52325. PubMed ID: 33904225 [TBL] [Abstract][Full Text] [Related]
11. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
13. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996 [TBL] [Abstract][Full Text] [Related]
14. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260 [TBL] [Abstract][Full Text] [Related]
15. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models. Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308 [TBL] [Abstract][Full Text] [Related]
17. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor. Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM Front Immunol; 2022; 13():871874. PubMed ID: 35898497 [TBL] [Abstract][Full Text] [Related]
18. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851 [TBL] [Abstract][Full Text] [Related]
19. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736 [TBL] [Abstract][Full Text] [Related]